Xencor Inc.

10/10/2024 | Press release | Distributed by Public on 10/10/2024 06:21

Xencor Presents Preclinical Data on XmAb942, a High Potency Extended Half Life Anti TL1A Antibody, to be Developed for Patients with Inflammatory Bowel Diseases

Read this content
Click here to read the original version at the source's official website. The text of this article is not available at the moment.